Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
In this article
Swiss pharmaceutical giant Novartis
is nearing a deal to buy biotechnology company Avidity Biosciences
for more than $70 a share, Bloomberg News reported, citing a person familiar with the matter.
A deal could be announced as early as Sunday, the report said.
Novartis compra Avidity Biosciences per 12 miliardi di dollari
Novartis comprerà Avidity Biosciences per 12 miliardi di dollari
Novartis compra Avidity Biosciences per 12 miliardi di dollari - Notizie - Ansa.it
Novartis kauft Avidity für zwölf Milliarden Dollar
Novartis to buy Avidity Biosciences for $12bn
Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
